StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.
Amid a pullback, health-care companies are preparing for the next phase of the Affordable Care Act.
Investors should only take risks that the market rewards--and that they can live with.
Although 2015 may be rocky, both Baxter and Baxalta should see significant margin expansion and growth in the long term, says Morningstar's Karen Andersen .
Not crushing on IPOs, Facebook's virtual strategy, a setback for Citi, and more.
Cost and scale advantages, as well as greater product focus in the future, are positives for this wide-moat health-care name.
Morningstar CEO of the Year finalist John Martin's smart capital-allocation decisions have helped drive a 100-fold increase in this biopharmaceutical's stock since he took over in 1996.
With an improving pipeline and a new manufacturing technology, Amgen is on the path to stabilizing its moat trend.
These three CEOs have been sound stewards of shareholder capital.